Small study finds benefit from convalescent plasma in severe COVID-19Preliminary data from a small study published today in Nature Medicine suggests convalescent plasma may have some efficacy in patients with severe COVID-19.The retrospective, propensity score-matched case-control study involved 39 patients who received convalescent plasma for severe or life-threatening COVID-19 at Mount Sinai Hospital in New York from Mar 20 to Apr 20.
The patients, who were an average age of 55 and had few baseline comorbidities other than obesity (mean mass body index, 31.7), received convalescent plasma under compassionate use guidelines an average of 4 days after admission.